Biochemistry-first molecular monograph · Version 5.1 · Updated 24 August 2026
Selank
A tuftsin-related neuroactive heptapeptide
The sequence produces measurable transcriptional and circuit-level responses connected to GABA-related and neuroimmune systems.
This monograph evaluates Selank, the synthetic tuftsin-related heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. It distinguishes intranasal human observations from parenteral animal experiments and from the biology of tuftsin itself.
This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.
Epistemological position
The causal chain carries the science.
Identity establishes what exists. Biochemistry establishes what can react. Pharmacology establishes whether the reaction is reachable. Physiology establishes what the system does with it. Statistical human observation comes last and adjudicates only the route, exposure, population and outcome actually studied.
A population average cannot identify a molecule, create a mechanism or decide an individual response. A demonstrated mechanism remains bounded by the causal step shown; a terminal study can confirm or refute its translation under specified conditions, never rewrite the underlying chemistry.
Molecular dossier
The entity before the outcome.
- ENTITY
- Thr-Lys-Pro-Arg-Pro-Gly-Pro, a tuftsin-related heptapeptide
- BIOCHEMICAL CLASS
- Neuroimmune regulatory peptide
- PRIMARY SYSTEM
- GABA-related transcription · neurotrophic signalling · immune–neural communication
- IDENTITY BOUNDARY
- Selank, tuftsin and Selank fragments are related but distinct. Intranasal human administration and parenteral animal administration cannot share exposure assumptions.
Action ledger
Describe the action before judging its value.
Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.
Attributed biochemical action
The sequence produces measurable transcriptional and circuit-level responses connected to GABA-related and neuroimmune systems.
Exposure and reachability
Route-specific systemic exposure and human pharmacokinetics are limited. Evidence from intranasal administration cannot establish injectable pharmacology.
Physiological direction is contextual
Anxiety, attention and cognitive control arise from distributed neural and immune networks rather than one transmitter concentration. GABA-related transcription, neurotrophic signalling, autonomic state, sleep and inflammatory context may converge, but an acute network change is not equivalent to durable functional regulation. Route-specific exposure remains the bridge between molecular signal and brain physiology.
Individual adjudication boundary
A proximal binding model and replicated human route-specific exposure-response relationship. Gene-expression similarity to GABA or an imaging change does not prove benzodiazepine-like pharmacology, durable anxiolysis or injectable efficacy.
Causal map with terminal adjudication
The scientific hierarchy is explicit.
I established; II partial and distributed; III limited by route-specific PK
The sequence produces measurable transcriptional and circuit-level responses connected to GABA-related and neuroimmune systems.
Class C/D for intranasal anxiety signals; E for injectable claims
This descriptor applies only to the named route, population and outcome. It neither ranks nor creates the molecule’s biochemical science.
Translation boundary
A proximal binding model and replicated human route-specific exposure-response relationship.
What must not be inferred
Gene-expression similarity to GABA or an imaging change does not prove benzodiazepine-like pharmacology, durable anxiolysis or injectable efficacy.
Historical and international corpus
Old research is not absent research.
Selank emerged from the Soviet/Russian regulatory-peptide tradition and has decades of Russian preclinical and clinical work. The exact molecule is not 100 years old, but a PubMed-only English-language scan materially understates its research history.
Russian-language indexed records are scientific evidence, not an administrative footnote. Their methods, comparators, route and reporting completeness must be appraised individually rather than accepted or discarded by geography.
Tuftsin biology was converted into a stabilised regulatory peptide
Selank extends the tuftsin tetrapeptide with Pro-Gly-Pro. This programme arose from a research tradition focused on short regulatory peptides, stress physiology and intranasal delivery; family history informs design but does not replace Selank-specific experiments.[2][3]
Russian clinical and comparative records must remain visible
A Russian-language comparative report in 60 patients and other clinical reports provide direct human information on intranasal use, psychometric outcomes and biological correlates. Limited blinding and reporting detail reduce precision; they do not turn the studies into no evidence.[1][8]
Mechanistic and biochemical calculus
Constraint, measurement and inference are not the same claim.
A biochemical proposition can be powerful without a clinical trial, but its premises, exposure and domain must remain explicit. Each statement below is labelled by the operation that supports it.
Sequence extension changes the entity
Adding Pro-Gly-Pro to tuftsin changes molecular mass, cleavage sites and potential exposure. A tuftsin effect can motivate a Selank hypothesis but cannot close it.[3]
Network response is broader than one receptor
GABA-related transcription, BDNF-linked effects, monoaminergic observations and immune gene responses indicate a distributed regulatory programme. Similarity to GABA does not demonstrate binding at a benzodiazepine site.[2][4][5][6]
Clinical signal and mechanism were measured together
The Russian comparative study paired symptom scales with serum leu-enkephalin activity. This is mechanistically richer than a symptom-only report, while still insufficient to establish blinded placebo effect size or durable recurrence prevention.[8]
Complete scientific web editionOpen the full causal analysis and referencesThe decision-grade summary remains above. The complete publication stays available here and as a downloadable PDF.
Causal architecture
From molecular event to organismal hypothesis.
GABA-related does not mean GABA-equivalent
Rodent cortical transcription after Selank overlaps with parts of the GABA response. This supports network interaction, while leaving direct receptor binding, circuit localisation and human symptom translation as separate questions.[2]
What is established
✓ Defined heptapeptide
✓ Preclinical GABA-related programme
✓ Intranasal human administration reported
What remains unresolved
? Human route-specific PK
? Controlled clinical magnitude
? Parenteral exposure and safety
Causal hierarchy
Seven evidentiary layers. No category substitution.
Levels I-V build the causal and translational model. Human observations and controlled clinical trials then test the complete proposition under the route, exposure, population and outcome actually studied. A trial is terminal adjudication, not the source of molecular truth.
IMolecular identity and chemistryWhat exact sequence, terminal chemistry, formulation and route exist?
IIBiochemistry and target architectureWhat reactions, binding events and signalling steps are physically possible?
IIICells and ex-vivo tissuesWhat changes in the relevant cell or isolated tissue system?
IVAnimal and in-vivo pharmacologyDoes exposure reach the mechanism in an integrated organism?
VIntegrated physiology and translationHow do tissue state, feedback, dose and individual terrain alter the response?
VIHuman PK and observational signalIs the entity present, tolerated and associated with a signal in humans?
VIIControlled clinical trialsDoes the specified protocol change a prespecified patient-relevant outcome?
Method applied to Selank
Where this molecule’s evidence can, and cannot, travel.
The complete corpus-wide attribution rules are published in the scientific methodology. This is their molecule-specific application.
Entity rule applied
Selank, tuftsin and Selank fragments are related but distinct. Intranasal human administration and parenteral animal administration cannot share exposure assumptions.
Reachability rule applied
Route-specific systemic exposure and human pharmacokinetics are limited. Evidence from intranasal administration cannot establish injectable pharmacology. The decisive exposure boundary for Selank therefore remains molecule-, formulation- and route-specific.
Causal-strength rule applied
The sequence produces measurable transcriptional and circuit-level responses connected to GABA-related and neuroimmune systems. This places the present causal depth at i established; ii partial and distributed; iii limited by route-specific pk. That grade describes which links in the mechanism have been demonstrated; it is not a consumer rating and cannot be converted into a general promise of benefit.
Human-adjudication rule applied
Class C/D for intranasal anxiety signals; E for injectable claims. This terminal descriptor answers only the population, route, exposure and outcome actually observed; it neither upgrades nor cancels a different link in Selank’s causal chain.
Translation rule applied
A proximal binding model and replicated human route-specific exposure-response relationship. Gene-expression similarity to GABA or an imaging change does not prove benzodiazepine-like pharmacology, durable anxiolysis or injectable efficacy.
Falsification rule applied
The interpretation must change if any of its decisive propositions fail. For Selank, the predeclared tests are: Lack of reproducible GABA-related or neurophysiological response would weaken the proposed network. Absent measurable intranasal exposure would force reinterpretation of the human signal. No symptom benefit despite a replicated imaging response would falsify imaging-as-efficacy reasoning. These are active boundaries on the conclusion, not research questions appended after a favourable narrative.
Foundational synthesis
Molecular identity and entity resolution
Selank is a synthetic heptapeptide related to tuftsin. The clinically reported intranasal route and any proposed parenteral route are different exposure experiments.
Foundational synthesis
Biochemical mechanism and target architecture
Proposed actions include GABAergic modulation, neurotrophic pathways and immune–neural communication. Much of the causal programme remains preclinical.
Foundational synthesis
In-vivo pharmacology and exposure
Route-specific systemic exposure and human pharmacokinetics are limited. Evidence from intranasal administration cannot establish injectable pharmacology.
Foundational synthesis
Integrated physiology and individual terrain
Anxiety, attention and cognitive control arise from distributed neural and immune networks rather than one transmitter concentration. GABA-related transcription, neurotrophic signalling, autonomic state, sleep and inflammatory context may converge, but an acute network change is not equivalent to durable functional regulation. Route-specific exposure remains the bridge between molecular signal and brain physiology.
Foundational synthesis
Terminal human stress-test
A comparative report in 60 patients with anxiety and somatoform disorders described anxiolytic and mild cognitive effects relative to phenazepam, but accessible reporting leaves randomisation, blinding, allocation and endpoint hierarchy insufficiently resolved.
Foundational synthesis
Counterevidence and causal boundaries
Small human reports establish administration and a signal worth studying; they do not establish broad anxiolysis, cognitive enhancement or injectable efficacy.
Foundational synthesis
Scientific conclusion
Selank has a partial mechanistic chain and limited, route-bound human evidence. Scientific translation requires route-specific PK, tolerability, systemic exposure and controlled outcomes.
Extended analysis
Sequence and relationship to tuftsin
Selank contains the tuftsin sequence Thr-Lys-Pro-Arg extended by Pro-Gly-Pro. The extension can change stability, tissue exposure and biological action. Tuftsin literature may support a mechanistic family relationship but cannot be treated as direct evidence for Selank.[1][3]
Human reports principally concern intranasal administration, while many mechanistic experiments use intraperitoneal dosing in rodents. Those routes create different absorption, concentration-time and tissue-distribution questions. Route is therefore part of the evidence identity.[1][2][4]
Extended analysis
GABA-related transcriptional programme
In rat frontal cortex, Selank and GABA produced correlated changes in expression of genes involved in neurotransmission. Forty-five genes changed one hour after administration and twenty-two at three hours in the reported experiment. This supports interaction with GABA-related regulatory networks without demonstrating direct benzodiazepine-site agonism.[2]
Gene-expression similarity is a mechanistic clue, not proof of identical pharmacology or clinical effect. Receptor binding, circuit function, behavioural output and human anxiety symptoms remain separate levels of inference.[2]
Extended analysis
Neurotrophic and immune-linked mechanisms
Rodent experiments have connected Selank with BDNF regulation, memory behaviour and monoaminergic balance under stress or injury models. These findings broaden the hypothesis beyond acute anxiolysis but remain preclinical and model dependent.[5]
Mouse spleen studies found changes in inflammation-related gene expression after Selank or its fragments, including time-dependent changes in C3, Casp1, Il2rg and Xcr1. This supports immune-neural pleiotropy but does not identify a validated clinical immune indication.[4][6]
Extended analysis
Human anxiety signal
A comparative study enrolled 60 patients with phobic-anxiety, generalised-anxiety and somatoform diagnoses and reported anxiolytic and mild nootropic effects relative to phenazepam, with persistence after treatment. The indexed abstract does not fully resolve randomisation, allocation concealment, blinding or endpoint hierarchy.[1]
The report establishes a human clinical signal worth reproducing. It does not establish effect magnitude against modern comparators or placebo, does not define long-term recurrence and cannot support an injectable claim.[1]
Extended analysis
Human neurophysiology
A resting-state functional-connectivity study of 52 healthy participants examined Selank, Semax and placebo and reported changes involving the right amygdala and temporal regions. Imaging demonstrates a measurable neural response but is not a clinical anxiety endpoint.[7]
Small imaging experiments are sensitive to preprocessing, multiplicity and timing. They can refine circuit hypotheses and dose windows; they cannot establish durable symptom benefit, comparative efficacy or safety in a patient population.[7]
Extended analysis
Translation boundary
Selank has exact molecular identity, a coherent preclinical programme and limited human intranasal signals. Missing elements include route-specific PK, robust placebo-controlled outcomes, repeated-use safety and independent replication outside a concentrated research network.[1][2][7]
The correct conclusion is not that mechanism is absent. It is that the chain from sequence to human exposure to reproducible patient benefit remains incomplete. Each additional route constitutes a new pharmacological experiment.[1][2]
Evidence atlas
Every claim keeps its experimental address.
12 claim units are mapped to their evidentiary layer, experimental frame and source records. The layer describes what the evidence can answer; it is not a popularity score.
| Layer | Experimental frame | Finding and boundary | Sources |
|---|---|---|---|
| VIHuman exposure or signal | Sequence and relationship to tuftsin · claim 1 | Selank contains the tuftsin sequence Thr-Lys-Pro-Arg extended by Pro-Gly-Pro. The extension can change stability, tissue exposure and biological action. Tuftsin literature may support a mechanistic family relationship but cannot be treated as direct evidence for Selank. | [1][3] |
| VIHuman exposure or signal | Sequence and relationship to tuftsin · claim 2 | Human reports principally concern intranasal administration, while many mechanistic experiments use intraperitoneal dosing in rodents. Those routes create different absorption, concentration-time and tissue-distribution questions. Route is therefore part of the evidence identity. | [1][2][4] |
| IVIntegrated in-vivo model | GABA-related transcriptional programme · claim 1 | In rat frontal cortex, Selank and GABA produced correlated changes in expression of genes involved in neurotransmission. Forty-five genes changed one hour after administration and twenty-two at three hours in the reported experiment. This supports interaction with GABA-related regulatory networks without demonstrating direct benzodiazepine-site agonism. | [2] |
| VIHuman exposure or signal | GABA-related transcriptional programme · claim 2 | Gene-expression similarity is a mechanistic clue, not proof of identical pharmacology or clinical effect. Receptor binding, circuit function, behavioural output and human anxiety symptoms remain separate levels of inference. | [2] |
| IVIntegrated in-vivo model | Neurotrophic and immune-linked mechanisms · claim 1 | Rodent experiments have connected Selank with BDNF regulation, memory behaviour and monoaminergic balance under stress or injury models. These findings broaden the hypothesis beyond acute anxiolysis but remain preclinical and model dependent. | [5] |
| IVIntegrated in-vivo model | Neurotrophic and immune-linked mechanisms · claim 2 | Mouse spleen studies found changes in inflammation-related gene expression after Selank or its fragments, including time-dependent changes in C3, Casp1, Il2rg and Xcr1. This supports immune-neural pleiotropy but does not identify a validated clinical immune indication. | [4][6] |
| VIHuman exposure or signal | Human anxiety signal · claim 1 | A comparative study enrolled 60 patients with phobic-anxiety, generalised-anxiety and somatoform diagnoses and reported anxiolytic and mild nootropic effects relative to phenazepam, with persistence after treatment. The indexed abstract does not fully resolve randomisation, allocation concealment, blinding or endpoint hierarchy. | [1] |
| VIHuman exposure or signal | Human anxiety signal · claim 2 | The report establishes a human clinical signal worth reproducing. It does not establish effect magnitude against modern comparators or placebo, does not define long-term recurrence and cannot support an injectable claim. | [1] |
| VIHuman exposure or signal | Human neurophysiology · claim 1 | A resting-state functional-connectivity study of 52 healthy participants examined Selank, Semax and placebo and reported changes involving the right amygdala and temporal regions. Imaging demonstrates a measurable neural response but is not a clinical anxiety endpoint. | [7] |
| VIHuman exposure or signal | Human neurophysiology · claim 2 | Small imaging experiments are sensitive to preprocessing, multiplicity and timing. They can refine circuit hypotheses and dose windows; they cannot establish durable symptom benefit, comparative efficacy or safety in a patient population. | [7] |
| VIIControlled human proposition | Translation boundary · claim 1 | Selank has exact molecular identity, a coherent preclinical programme and limited human intranasal signals. Missing elements include route-specific PK, robust placebo-controlled outcomes, repeated-use safety and independent replication outside a concentrated research network. | [1][2][7] |
| VIHuman exposure or signal | Translation boundary · claim 2 | The correct conclusion is not that mechanism is absent. It is that the chain from sequence to human exposure to reproducible patient benefit remains incomplete. Each additional route constitutes a new pharmacological experiment. | [1][2] |
Methods and coverage
A reproducible boundary, not an implied exhaustive review.
This is a curated mechanistic monograph built from primary records. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.
- SEARCH SURFACE
- PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
- QUERY FRAME
- Selank · tuftsin analogue · anxiety · GABA · BDNF · intranasal peptide · functional connectivity
- EVIDENCE CUTOFF
- 24 August 2026
- ENTITY EXCLUSION
- Selank, tuftsin and Selank fragments are related but distinct. Intranasal human administration and parenteral animal administration cannot share exposure assumptions.
- TRACEABILITY
- 12 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 8 cited records in the complete corpus.
- INTERPRETIVE RULE
- Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.
Falsification map
What could make the proposition wrong?
A scientific monograph must state not only why a mechanism may hold, but what observation would weaken or overturn the inference.
- 01Lack of reproducible GABA-related or neurophysiological response would weaken the proposed network.
- 02Absent measurable intranasal exposure would force reinterpretation of the human signal.
- 03No symptom benefit despite a replicated imaging response would falsify imaging-as-efficacy reasoning.
Research agenda
What would materially change the conclusion?
A useful research agenda resolves the weakest link in the identity-to-outcome chain. It does not merely add more observations of the same type.
- 01Human intranasal PK and bioavailability
- 02Placebo-controlled anxiety trials with prespecified endpoints
- 03Independent replication
- 04Longitudinal tolerability and withdrawal assessment
- 05Circuit-response correlation with symptoms
- 06Separate parenteral exposure programme before injectable claims
Cited primary evidence corpus
8 source records used in this publication.
Reference numbers resolve directly to indexed records. This corpus documents the claims made here; it is not presented as an exhaustive systematic-review search. Index access does not upgrade the evidentiary class of a study.
- [1]Medvedev et al. Zh Nevrol Psikhiatr. 2014;114:17–22.PMID 25176261 ↗
- [2]Volkova et al. Front Pharmacol. 2016;7:31.PMID 26924987 ↗
- [3]Uchakina et al. Zh Nevrol Psikhiatr. 2008;108:71–75.PMID 18577961 ↗
- [4]Kolik et al. Selank regulates BDNF and memory effects in an ethanol-withdrawal rat model. Bull Exp Biol Med. 2019.PMID 31625062 ↗
- [5]Andreeva et al. Inflammation-related gene expression in mouse spleen under Selank. Mol Immunol. 2011.PMID 21609736 ↗
- [6]Kolomin et al. Temporal dynamics of inflammation-related genes under Selank. Peptides. 2013.PMID 24291245 ↗
- [7]Panikratova et al. Functional connectomic approach to Selank and Semax effects. Dokl Biol Sci. 2020.PMID 32342318 ↗
- [8]Zozulia et al. Efficacy and possible mechanisms of Selank in generalised anxiety disorder and neurasthenia. Zh Nevrol Psikhiatr. 2008. Russian-language randomised comparative study.PMID 18454096 ↗
Permanent citation
Cite this publication
Wibowo V. Selank: Biochemical, Mechanistic and Physiological Monograph. Clinic Terrain Clinical Intelligence Unit. Version 5.1. Updated 24 August 2026.
https://www.clinicterrain.com/research/peptides/selankPublication and reference-verification method →Authorship and accountability
Valentine Wibowo, Clinical Researcher, Clinic Terrain Clinical Intelligence Unit, performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent peer review.
No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.